TrialClinical endocrinology2014

Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.

Pinchas Cohen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.